NCT00137800View on ClinicalTrials.gov

Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

May 31, 2005

Study Completion Date

March 31, 2007

Conditions
Non-Small-Cell Lung Carcinoma
Interventions
DRUG

OSI-774 (Tarceva)

Once daily without interruption as long as there is no disease progression or serious side effects experienced.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00137800 - Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients | Biotech Hunter | Biotech Hunter